BlockBeats News, August 20th, UBS Group announced that it has raised Moderna's (MRNA.O) price target from $50 to $150.

Earlier reports stated that Moderna, in collaboration with Mercedez, has achieved significant success in a Phase III clinical trial of a personalized mRNA cancer vaccine targeting high-risk melanoma. This is the world's first mRNA cancer therapy to prove effective in a large-scale Phase III trial. Following the announcement, Moderna's stock price surged by nearly 177% in a single day.